Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial

Delamanid has been demonstrated to be safe and effective for treatment of adult multidrug-resistant tuberculosis (MDR-TB) and has been approved by the European Commission for treatment of pediatric MDR-TB patients at least 10 kg in weight, making the drug no longer limited to adults. A 10-day phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Prats, Anthony J., Frias, Melchior, van der Laan, Louvina, De Leon, Anjanette, Gler, Maria Tarcela, Schaaf, H. Simon, Hesseling, Anneke C., Malikaarjun, Suresh, Hafkin, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112969/
https://www.ncbi.nlm.nih.gov/pubmed/35404075
http://dx.doi.org/10.1128/aac.02144-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112969/
https://www.ncbi.nlm.nih.gov/pubmed/35404075
http://dx.doi.org/10.1128/aac.02144-21

Ejemplares similares